MARKET

HOWL

HOWL

Werewolf Therapeutics, Inc.
NASDAQ
0.4500
+0.0276
+6.53%
Opening 13:57 05/22 EDT
OPEN
0.4200
PREV CLOSE
0.4224
HIGH
0.4633
LOW
0.4200
VOLUME
485.00K
TURNOVER
--
52 WEEK HIGH
2.380
52 WEEK LOW
0.4040
MARKET CAP
21.87M
P/E (TTM)
-0.3723
1D
5D
1M
3M
1Y
5Y
1D
Why e.l.f. Beauty Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Weekly Report: what happened at HOWL last week (0511-0515)?
Weekly Report · 4d ago
Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation
Simply Wall St · 05/14 10:58
Werewolf Therapeutics director Luke Evnin sells 44,679 shares worth $24,127.66
PUBT · 05/13 20:07
Major Werewolf Therapeutics Stakeholder Makes a Big Move on Wall Street
TipRanks · 05/13 02:07
Werewolf Therapeutics director Luke Evnin disposes 407,574 shares for $294,971.41
PUBT · 05/12 23:48
RA Capital Management disposes 565,167 Werewolf Therapeutics shares worth $389,277
PUBT · 05/12 22:27
Weekly Report: what happened at HOWL last week (0504-0508)?
Weekly Report · 05/11 09:50
More
About HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Webull offers Werewolf Therapeutics Inc stock information, including NASDAQ: HOWL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOWL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HOWL stock methods without spending real money on the virtual paper trading platform.